Breaking News Instant updates and real-time market news.

BIIB

Biogen

$251.74

-3.28 (-1.29%)

, CLVS

Clovis

$59.97

0.27 (0.45%)

10:38
06/19/17
06/19
10:38
06/19/17
10:38

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Biogen (BIIB) upgraded to Neutral from Sell at UBS with analyst Carter Gould saying he sees an improved risk/reward and a positive near-term setup going into the second quarter earnings call and strategic review. 2. Clovis (CLVS) upgraded to Neutral from Sell at Chardan. 3. Cedar Fair (FUN) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Christopher Prykull saying early season indicators appear strong as several management teams noted ongoing leisure strength at the firm's Lodging, Gaming Restaurant and Leisure Conference. 4. Athene Holding (ATH) upgraded to Outperform from Neutral at Credit Suisse with analyst John Nadel saying he believes the probability is increasing that Athene will use acquisitions to accelerate its balance sheet and earnings growth. 5. Credit Suisse (CS) upgraded to Buy from Hold at Deutsche Bank with analyst Kinner Lakhani saying an inflection in the company's operating results is near following the recent anticipated capital raise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

BIIB

Biogen

$251.74

-3.28 (-1.29%)

CLVS

Clovis

$59.97

0.27 (0.45%)

FUN

Cedar Fair

$71.83

1.15 (1.63%)

ATH

Athene Holding

$49.74

0.87 (1.78%)

CS

Credit Suisse

$14.01

0.4653 (3.44%)

BIIB Biogen
$251.74

-3.28 (-1.29%)

06/14/17
MSCO
06/14/17
NO CHANGE
MSCO
Alexion new CFO 'highly credible,' should calm investors, says Morgan Stanley
After Alexion (ALXN) named Biogen (BIIB) CFO Paul Clancy as its new CFO, Morgan Stanley analyst Matthew Harrison calls Clancy "a highly credible choice." Harrison thinks that the appointment of Clancy should ease investors' fears about the "stability" of the company's Soliris drug. The analyst adds that the CEO's forecast for "double digit growth," along with Clancy's appointment, should boost the stock today. He keeps a $138 price target and Overweight rating on the shares.
06/14/17
FBCO
06/14/17
NO CHANGE
Target $164
FBCO
Outperform
Former Biogen CFO a 'strong hire' for Alexion, says Credit Suisse
Credit Suisse analyst Alethia Young said Alexion's (ALXN) poaching of biopharma CFO veteran Paul Clancy from Biogen (BIIB) is a strong hire for the former and a loss for the operations of the latter. She expects Alexion shares to be higher today, and for Biogen to be weak, following the news. Young keeps an Outperform rating on Alexion.
06/14/17
UBSW
06/14/17
NO CHANGE
Target $140
UBSW
Buy
Alexion CFO a significant hire, says UBS
UBS analyst Martin Auster noted Alexion (ALXN) hired Biogen's (BIIB) Paul Clancy as CFO and believes it has a positive read-through as he is well known by the Street and is received favorably. The analyst also believes the company can restore value through a combination of execution on growth drivers and a reduction of its implied risk premium in light of recent regulatory headwinds. Auster reiterated his Buy rating and $140 price target on Alexion shares.
06/19/17
UBSW
06/19/17
UPGRADE
Target $270
UBSW
Neutral
Biogen upgraded to Neutral from Sell at UBS
UBS analyst Carter Gould upgraded Biogen to Neutral and raised his price target for the shares to $270 from $262. The biotech closed Friday down $3.28 from $251.74. The analyst sees an improved risk/reward and a positive near-term setup going into the Q2 earnings call and strategic review. The competitive threat to Biogen's Spinraza from gene therapy is now priced into the shares and sentiment is near a bottom, Gould tells investors in a research note. The analyst is also "incrementally more constructive" on aducanumab. Gould thinks the stock's underperformance "stops here."
CLVS Clovis
$59.97

0.27 (0.45%)

06/19/17
CHDN
06/19/17
UPGRADE
CHDN
Neutral
Clovis upgraded to Neutral from Sell at Chardan
06/19/17
STFL
06/19/17
NO CHANGE
Target $125
STFL
Buy
Clovis price target raised to $125 from $86 at Stifel
06/19/17
RAJA
06/19/17
NO CHANGE
RAJA
Market Perform
Raymond James remains cautious on Tesaro, takeout less likely
Raymond James analyst Christopher Raymond remains cautious on Tesaro (TSRO) shares following Clovis' (CLVS) Rubraca ARIEL3 results. The analyst said PFS measures between the Clovis Rubraca and Tesaro's Zejula are remarkably similar among ovarian cancer patients, making the PARP space much more competitive and crowded. Raymond believes a takeout of Tesaro based on Zejula's superior labeling is much less likely and reiterated his Market Perform rating on shares.
06/19/17
JEFF
06/19/17
NO CHANGE
Target $124
JEFF
Hold
Tesaro worth $80 per share on fundamentals, says Jefferies
Jefferies analyst Eun Yang views Clovis Oncology's (CLVS) data today for rucaparib as "highly competitive" to Tesaro's (TSRO) niraparib. The data from Clovis will likely impact any potential takeover premium for Tesaro, Yang tells investors in a research note. The analyst views Tesaro as being worth $80 per share on a fundamental basis. She has a Hold rating and $124 price target on the shares. Tesaro in early trading is down 5%, or $7.09, to $137.22.
FUN Cedar Fair
$71.83

1.15 (1.63%)

04/21/17
STFL
04/21/17
INITIATION
STFL
Buy
Cedar Fair initiated at Stifel
As noted earlier, Stifel started coverage of Cedar Fair with a $78 price target and a Buy rating. Stifel analyst Steven Wieczynski says that the company has delivered consistent results, while its planned utilization of additional land should enable its EBITDA growth to accelerate over the longer term. He thinks that the stock can deliver "sustainable upper-single to low-double digit total returns in perpetuity."
04/20/17
STFL
04/20/17
INITIATION
Target $78
STFL
Buy
Cedar Fair initiated with a Buy at Stifel
Stifel initiated Cedar Fair with a Buy and a $78 price target.
04/21/17
04/21/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Plains All American (PAA) initiated with an Outperform at Macquarie. 2. Wendy's (WEN) and McDonald's (MCD) were initiated with an Outperform at BMO Capital while Yum! Brands (YUM) was initiated with a Market Perform. 3. Cedar Fair (FUN), Six Flags (SIX), and SeaWorld (SEAS) were initiated with a Buy at Stifel. 4. Domino's Pizza (DPZ) initiated with a Buy at Guggenheim. 5. Cidara Therapeutics (CDTX) initiated with a Strong Buy at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/19/17
GSCO
06/19/17
UPGRADE
GSCO
Conviction Buy
Cedar Fair upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman analyst Christopher Prykull added Cedar Fair to the Conviction Buy List with an $81 price target telling investors early season indicators appear strong as several management teams noted ongoing leisure strength at the firm's Lodging, Gaming Restaurant and Leisure Conference. The analyst has increased confidence in its above consensus estimates and said weather has improved post Memorial Day.
ATH Athene Holding
$49.74

0.87 (1.78%)

04/03/17
MSCO
04/03/17
UPGRADE
Target $58
MSCO
Overweight
Athene Holding upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Nigel Dally upgraded Athene Holding to Overweight and raised his price target for the shares to $58 from $54. The analyst cites the recent pullback in the shares as well the company's growth and profitability, which he says is "well ahead" of peers.
04/04/17
04/04/17
UPGRADE
Target $58

Overweight
Athene Holding upgraded on profitability and growth at Morgan Stanley
As previously reported, Morgan Stanley upgraded Athene Holding to Overweight from Equal Weight with a $58 price target. Analyst Nigel Dally told investors Athene is poised for growth and profitability well ahead of its peers, driven by product expansion and distribution, and said the recent pullback provides solid upside potential.
06/19/17
FBCO
06/19/17
UPGRADE
Target $66
FBCO
Outperform
Athene Holding upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst John Nadel upgraded Athene Holding to Outperform and raised his price target for the shares to $66 from $55. The analyst believes the probability is increasing that Athene will use acquisitions to accelerate its balance sheet and earnings growth. Further, following the recent upgrade by AM Best, the company is better positioned to participate in the "growing pension risk transfer opportunity."
04/04/17
MSCO
04/04/17
UPGRADE
MSCO
Overweight
Athene Holding upgraded to Overweight from Equal Weight at Morgan Stanley
CS Credit Suisse
$14.01

0.4653 (3.44%)

02/17/17
02/17/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Workday (WDAY) upgraded to Overweight from Neutral at Piper Jaffray by analyst Alex Zukin, who said his channel checks indicate the company's fundamentals have improved materially since last quarter. He notes that his checks on Workday and Salesforce (CRM) "came back the strongest in recent memory." 2. Tempur Sealy (TPX) upgraded to Outperform from Market Perform at Raymond James, as analyst Budd Bugatch said all the bad news is known and the improvement in revenues and earnings will become more visible as 2017 unfolds. 3. Capital One (COF) upgraded to Buy from Neutral at Goldman Sachs by analyst Ryan Nash, who raised his price target for the shares to $110 from $106. Almost all of the bank's increases in losses during 2016 can be explained by "growth math," which should have a "finite life to it," Nash tells investors. 4. Credit Suisse (CS) upgraded to Overweight from Equal Weight at Morgan Stanley by analyst Magdalena Stoklosa, who thinks connectivity across businesses, capital utilization, and earnings quality from here will result in more predictable earnings. 5. Chemours (CC) upgraded to Positive at Susquehanna by analyst Don Carson, who sees significant upside he sees to management's modest EBITDA guidance due to greater momentum in TiO2 prices. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/19/17
DBAB
06/19/17
UPGRADE
DBAB
Buy
Credit Suisse upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Kinner Lakhani upgraded Credit Suisse to Buy with a CHF 15 price target. An inflection in the company's operating results is near following the recent anticipated capital raise, the analyst contends.
06/19/17
BOFA
06/19/17
INITIATION
Target $17.19
BOFA
Buy
Credit Suisse resumed with a Buy at BofA/Merrill
BofA/Merrill analyst Andrew Stimpson resumed coverage on Credit Suisse with a Buy and a $17.20 price target.
02/17/17
MSCO
02/17/17
UPGRADE
MSCO
Overweight
Credit Suisse upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Magdalena Stoklosa upgraded Credit Suisse to Overweight saying connectivity across businesses, capital utilization, and earnings quality from here will result in more predictable earnings delivery.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$376.40

4.16 (1.12%)

08:01
06/22/17
06/22
08:01
06/22/17
08:01
Periodicals
Tianjin not participating in Tesla's China project at this time, Reuters says »

Tianjin Motors says it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MNK

Mallinckrodt

$45.37

2.06 (4.76%)

08:00
06/22/17
06/22
08:00
06/22/17
08:00
Options
Mallinckrodt call buyer realizes 74% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:00
06/22/17
06/22
08:00
06/22/17
08:00
General news
Breaking General news story  »

New York Federal Reserve…

ORCL

Oracle

$46.33

0.49 (1.07%)

07:59
06/22/17
06/22
07:59
06/22/17
07:59
Upgrade
Oracle rating change  »

Oracle upgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

BRK.A

Berkshire Hathaway

$254,400.00

-1460 (-0.57%)

, BRK.B

Berkshire Hathaway

$169.62

-0.93 (-0.55%)

07:57
06/22/17
06/22
07:57
06/22/17
07:57
Hot Stocks
Berkshire to invest up to C$400M in Home Capital, provide C$2B line of credit »

Canada's Home…

BRK.A

Berkshire Hathaway

$254,400.00

-1460 (-0.57%)

BRK.B

Berkshire Hathaway

$169.62

-0.93 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$153.73

-0.34 (-0.22%)

, AMZN

Amazon.com

$1,002.23

9.64 (0.97%)

07:56
06/22/17
06/22
07:56
06/22/17
07:56
Periodicals
McDonald's teams up with UberEats in Britain, Engadget reports »

McDonald's (MCD) is…

MCD

McDonald's

$153.73

-0.34 (-0.22%)

AMZN

Amazon.com

$1,002.23

9.64 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

KMDA

Kamada

$7.50

-0.05 (-0.66%)

07:55
06/22/17
06/22
07:55
06/22/17
07:55
Technical Analysis
Technical View: Kamada dives after withdrawing MAA for AAT therapy with EMA »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

NEP

NextEra Energy Partners

$35.11

0.03 (0.09%)

, NEE

NextEra Energy

$141.06

-0.9 (-0.63%)

07:55
06/22/17
06/22
07:55
06/22/17
07:55
Conference/Events
NextEra Energy and NextEra Energy Partners to hold an investor meeting »

Investor Meeting to be…

NEP

NextEra Energy Partners

$35.11

0.03 (0.09%)

NEE

NextEra Energy

$141.06

-0.9 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 22

    Jun

LLY

Eli Lilly

$82.64

-0.11 (-0.13%)

07:55
06/22/17
06/22
07:55
06/22/17
07:55
Conference/Events
FDA Pediatric Oncology Subcommittee of Oncologic Drugs Committee holds a meeting »

The Pediatric Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SPLS

Staples

$8.66

-0.09 (-1.03%)

07:52
06/22/17
06/22
07:52
06/22/17
07:52
Recommendations
Staples analyst commentary  »

Staples LBO could work in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSM

TSMC

$36.71

0.58 (1.61%)

, QCOM

Qualcomm

$56.33

-0.46 (-0.81%)

07:51
06/22/17
06/22
07:51
06/22/17
07:51
Periodicals
TSMC receives 7nm chip orders from Qualcomm, DigiTimes reports »

TSMC (TSM) has secured…

TSM

TSMC

$36.71

0.58 (1.61%)

QCOM

Qualcomm

$56.33

-0.46 (-0.81%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTIC

Otonomy

$17.50

1.45 (9.03%)

07:50
06/22/17
06/22
07:50
06/22/17
07:50
Hot Stocks
Otonomy announces successful end-of-Phase 2 review by FDA for Otiprio »

Otonomy announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCS

Steelcase

$16.30

-0.2 (-1.21%)

07:50
06/22/17
06/22
07:50
06/22/17
07:50
Technical Analysis
Technical View: Steelcase drops sharply after earnings and outlook »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

TRGP

Targa Resources

$40.68

-0.73 (-1.76%)

07:49
06/22/17
06/22
07:49
06/22/17
07:49
Recommendations
Targa Resources analyst commentary  »

Targa Resources guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:47
06/22/17
06/22
07:47
06/22/17
07:47
General news
Futures slightly higher ahead of claims data »

Stock futures are trading…

DHI

D.R. Horton

$33.97

-0.2 (-0.59%)

, FOR

Forestar Group

$16.30

-0.1 (-0.61%)

07:45
06/22/17
06/22
07:45
06/22/17
07:45
Hot Stocks
D.R. Horton reiterates proposal to acquire 75% of Forestar Group »

D.R. Horton (DHI) said…

DHI

D.R. Horton

$33.97

-0.2 (-0.59%)

FOR

Forestar Group

$16.30

-0.1 (-0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPC

Edgewell Personal Care

$75.05

-0.67 (-0.88%)

07:45
06/22/17
06/22
07:45
06/22/17
07:45
Upgrade
Edgewell Personal Care rating change  »

Edgewell Personal Care…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$62.50

0.05 (0.08%)

07:44
06/22/17
06/22
07:44
06/22/17
07:44
Recommendations
Lumentum analyst commentary  »

Lumentum price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 26

    Jun

PRIM

Primoris

$23.84

-0.77 (-3.13%)

07:42
06/22/17
06/22
07:42
06/22/17
07:42
Hot Stocks
Primoris announces new pipeline construction awards valued at about $53M »

Primoris Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRSC

Sears Canada

$0.47

-0.115 (-19.69%)

07:42
06/22/17
06/22
07:42
06/22/17
07:42
Hot Stocks
Breaking Hot Stocks news story on Sears Canada »

Sears Canada trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$46.33

0.48 (1.05%)

07:41
06/22/17
06/22
07:41
06/22/17
07:41
Technical Analysis
Technical View: Oracle sharply higher after earnings, analyst actions »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

FCX

Freeport McMoRan

$11.21

-0.03 (-0.27%)

07:40
06/22/17
06/22
07:40
06/22/17
07:40
Periodicals
Freeport Indonesia says Grasberg operations normal despite strike, Reuters says »

Operations at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLVS

Clovis

$94.29

5.61 (6.33%)

07:38
06/22/17
06/22
07:38
06/22/17
07:38
Recommendations
Clovis analyst commentary  »

Clovis price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

FL

Foot Locker

$47.82

-2.51 (-4.99%)

, NKE

Nike

$52.59

1.03 (2.00%)

07:38
06/22/17
06/22
07:38
06/22/17
07:38
Recommendations
Foot Locker, Nike, Amazon.com analyst commentary  »

Foot Locker remains a key…

FL

Foot Locker

$47.82

-2.51 (-4.99%)

NKE

Nike

$52.59

1.03 (2.00%)

AMZN

Amazon.com

$1,002.23

9.64 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

BA

Boeing

$199.17

0.84 (0.42%)

07:37
06/22/17
06/22
07:37
06/22/17
07:37
Hot Stocks
Boeing: Customers announced orders, commitments for 571 airplanes at Paris show »

Boeing made several…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.